Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) is a low-priced trading equity that has started to garner attention as the stock bounces up the chart. The company recently announced a joint research agreement focused on pediatric applications of PV-10, an investigational ablative immunotherapy, as a potential treatment for childhood cancers. The research is lined up in cooperation with “POETIC”, The Pediatric Oncology Experimental Therapeutics Investigators Consortium, a group of 10 top-tier academic medical centers developing new pediatric cancer therapies.
Traders will note 52% tacked on to share pricing for the stock in the past week, a rally that has pushed up against longer standing distributive pressure in the stock. This is emblematic of the stock. PVCT has a track record that includes a number of dramatic bounces. Furthermore, the listing has benefitted from a jump in recent trading volume to the tune of nearly 320% over the long run average.
Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) promulgates itself as a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications.
Its prescription drug candidates include PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. In addition, it develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris.
Further, the company is developing over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.
Additionally, it develops medical device technologies for markets comprising cosmetic treatments, such as reduction of wrinkles and elimination of spider veins, and other cosmetic blemishes; and therapeutic uses, including photoactivation of PH-10, other prescription drugs, and non-surgical destruction of various skin cancers.
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Find out when $PVCT stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As discussed above, the company recently joined forces with POETIC, The Pediatric Oncology Experimental Therapeutics Investigators Consortium, a group of 10 top-tier academic medical centers developing new pediatric cancer therapies, to launch a joint research agreement focused on pediatric applications of PV-10, an investigational ablative immunotherapy, as a potential treatment for childhood cancers.
The program will involve collaboration with a number of NCI Cancer Centers that are part of the POETIC group including Memorial Sloan Kettering Cancer Center (MSK), Alberta Children’s Hospital, and other top-tier cancer centers of excellence.
“We are pleased to collaborate with Provectus on this shared vision to advance promising new approaches for cancer that ultimately could lead to new treatments for pediatric patients, leveraging PV-10’s novel characteristics and mechanism of action,” said Dr. Trippett, Co-Founder and Executive Director of POETIC.
The past few days have been a technical revolution in the stock, during which we have seen strong volume on a rally in perhaps the first time in at least 15 months. The move is promising in bounce terms, but the trend is clearly still unfavorable.
Earning a current market cap value of $4.9M, PVCT has a significant war chest ($266.17k) of cash on the books, which is balanced by virtually no total current liabilities. The company is pre-revenue at this point. We will update the story again soon as developments transpire. For continuing coverage on shares of $PVCT stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!